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doi:10.1Objective: The study objectives were to characterize the prognostic perspectives of pulmonary artery sarcoma
and to investigate the effect of distal embolectomy on the prognosis of surgical treatment of pulmonary artery
sarcoma.
Methods:Nine patients with pulmonary artery sarcomawere surgically treated at Anzhen Hospital, and the data
were retrospectively reviewed. Five patients underwent only pulmonary artery sarcoma resection, and 4 patients
underwent both pulmonary artery sarcoma resection and distal embolectomy.
Results: There was no in-hospital mortality. Four patients had lung ischemia-reperfusion injury, 3 of whom re-
covered with the support of extended ventilation and positive end-expiratory pressure, and 1 of whom recovered
with extracorporeal membrane oxygenation support. During the follow-up, 5 patients who did not undergo distal
embolectomy died 6 to 29 months after the procedure, with a median survival time of 10 months. Of the 4 pa-
tients undergoing distal embolectomy, 3 died 30, 37, and 43 months after the procedure, and 1 is still alive 39
months after the procedure. All 8 deaths were due to local or systemic recurrence. The patients who underwent
distal embolectomy lived longer than the patients who did not undergo distal embolectomy (log-rank test,
x2 ¼ 7.914, P ¼ .005).
Conclusions: Radical surgical resection provides the only chance of survival for patients with pulmonary artery
sarcoma, and distal embolectomy may further extend survival for these patients. (J Thorac Cardiovasc Surg
2011;142:1469-72)A
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DPulmonary artery sarcoma (PAS) is a rare and fatal neoplasm
that always arises from the central pulmonary arteries. Early
diagnosis and radical surgical resection offer the only
chance for survival.1,2 However, surgical intervention still
has some challenges, and the prognosis is poor even after
tumor resection.3 To characterize the prognostic perspec-
tives of the surgical treatment to PAS, we retrospectively re-
viewed the data of 9 patients with PAS who were admitted
and surgically treated at Anzhen Hospital from June 2000
to July 2007.PATIENTS AND METHODS
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study and waived the need to obtain patient consent for the study. Written
informed consent was obtained from each patient before surgery.e Department of Cardiac Surgerya and Department of Respiratory,b Beijing
en Hospital, Capital Medical University, Beijing Institute of Heart, Lung
lood Vessel Diseases, Beijing China; and Department of Cardiac Surgery,c
ng Daxin Hospital, Capital Medical University, Beijing China.
: This project was supported by Grant 81070041 from the National Nature
ce Foundation of China.
ures: Authors have nothing to disclose with regard to commercial support.
d for publication Dec 17, 2010; revisions received March 7, 2011; accepted
blication March 21, 2011; available ahead of print April 19, 2011.
for reprints: Hui-Li Gan, MD, PhD, Cardiac Surgery Department, Beijing
en Hospital, Capital Medical University, Beijing Institute of Heart, Lung
lood Vessel Diseases, Beijing 100029 China (E-mail: ganhuili@hotmail.
.
23/$36.00
ht  2011 by The American Association for Thoracic Surgery
016/j.jtcvs.2011.03.013
The Journal of Thoracic and CarPatients
Between June 2000 and July 2007, 9 patients with PAS were surgically
treated at Anzhen Hospital. The medical records were retrospectively re-
viewed to evaluate the clinical characteristics, operative findings, postoper-
ative courses, and long-term results. Patients’ mean age was 48.4  9.3
years (range, 35–67 years). Seven patients were female, and 2 patients
were male. Most patients presented with syncope (n ¼ 7), cough
(n ¼ 6), and dyspnea (n ¼ 9); they also had hemoptysis (n ¼ 4) and chest
pain (n¼ 1), with an average duration of symptoms of 4months (range, 1–7
months). Six patients had New York Heart Association (NYHA) functional
class III, and 3 patients had NYHA functional class IV; the 6-minute walk
distance was 289  76 m. One male patient had severe coronary disease,
and there were no comorbidities in the other 8 patients. All patients
underwent at least 1 or 2 diagnostic tests with pulmonary artery computed
tomography angiography (n ¼ 7), magnetic resonance imaging (n ¼ 4),
echocardiography (n ¼ 9), or pulmonary angiography (n ¼ 3). Before
and 2 weeks after the surgical procedure, all 9 patients underwent
pulmonary ventilation/perfusion scintigraphy. On the basis of the findings
of the imaging studies, 8 patients had chronic thromboembolic pulmonary
hypertension preoperatively. PAS was correctly diagnosed with the aid of
positron emission tomography preoperatively in only 1 patient. As shown
in Table 1, the histologic and immunochemical findings during or after the
surgical procedure in these 9 patients revealed the final diagnosis to be PAS.Surgical Techniques
All procedures were performed under general anesthesia and ap-
proached through a median sternotomy. The first 5 patients (patients
1–5) underwent PAS resection with the aid of moderate hypothermic car-
diopulmonary bypass (CPB), during which the pulmonary artery trunk
and both the left and right pulmonary arteries were opened, and the PAS
was resected via the pulmonary arteriotomy. In addition to the PAS resec-
tion, 4 patients (patients 6–9) underwent a further distal embolectomy with
the aid of CPB and deep hypothermic circulatory arrest, which included
evacuation of both the superimposed thrombosis and the metastasizeddiovascular Surgery c Volume 142, Number 6 1469
Abbreviations and Acronyms
CPB ¼ cardiopulmonary bypass
NYHA ¼ New York Heart Association
PAS ¼ pulmonary artery sarcoma
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DPAS embolus in the distal segmental pulmonary arteries. In all patients with
a sarcoma tumor that extended from the pulmonary valve to the pulmonary
artery trunk, the tumor was carefully peeled from the pulmonary valve and
the pulmonary arteries without valve prosthesis replacement or homograft
graft replacement. The main body of the PAS was fully resected in all pa-
tients. PAS tumor embolus and thromboembolic parts distal to the tumor
main body were completely evacuated only in patients 6 to 9, whereas pa-
tients 1 to 5 did not receive distal embolectomy. The CPB timewas 182.1
35.3 minutes for the whole group, the clamping time for the whole group
was 105.1  27.6 minutes, and the circulatory arrest time was 47.7 
13.6 minutes for patients 6, 7, 8, and 9.
Postoperative adjuvant treatment included radiation therapy for 2
patients (patients 1 and 7), chemotherapy for 2 patients (patients 5 and
6), and combined radiation and chemotherapy for 3 patients (patients 2,
4, and 8). Two patients (patients 3 and 9) did not receive any adjuvant
treatment.
Follow-up
Valid and complete follow-up information was obtained from all 9 pa-
tients through postal mail, e-mail, phone interviews, or outpatient depart-
ment visit. Screening by magnetic resonance imaging, pulmonary artery
computed tomography angiography, and echocardiography was performed
in all patients every 3months after PAS resection. The last follow-up for the
surviving patients was as late as October 2010.
Statistical Analysis
All statistical analyses were performed with SAS for Windows Version
8.2 (SAS Institute, Inc, Cary, NC). Categoric data are presented as total
numbers and relative frequencies. Continuous data are presented as mean
 standard deviation. Comparisons between the 2 groups (with or without
distal embolectomy) were made using the log-rank test as appropriate.RESULTS
Early Results
There was no in-hospital mortality. After the PAS resec-
tion procedure, 4 patients had pulmonary ischemia–reperfu-
sion injury, 1 of whom required extracorporeal membraneTABLE 1. Clinical characteristics and pathologic findings of patients with
Patient no. Age/sex Initial diagnosis Histologic subclassifi
1 35/F CTEPH Leiomyosarcoma
2 39/F CTEPH Undifferentiated sarco
3 43/M CTEPH Pleomorphic rhabdosa
4 54/F CTEPH Intimal sarcoma
5 52/F CTEPH Intimal sarcoma
6 50/F CTEPH Leiomyosarcoma
7 47/M CTEPH Intimal sarcoma
8 49/F CTEPH Intimal sarcoma
9 67/F PAS Intimal sarcoma
CTEPH, Chronic thromboembolic pulmonary hypertension; PAS, pulmonary artery sarco
1470 The Journal of Thoracic and Cardiovascular Suroxygenation as life support. Extracorporeal membrane
oxygenation was weaned 23 hours after installation, and
the patient was extubated 70 hours after the procedure.
The other 3 patients recovered through extended mechani-
cal ventilation and positive end-expiratory pressure support.
The mean length of intensive care unit stay after operation
was 48.7  25.8 hours (range, 27–74 hours). The mean
length of hospital stay after operation was 18.7  8.8
days (range, 10–29 days). One month after the operations,
the heart function of all patients improved from NYHA
functional class III or IV preoperatively to NYHA func-
tional class I, and the 6-minute walk distance increased
from 289  76 m preoperatively to 425  85 m
(P ¼ .0001). The results of the pulmonary ventilation/
perfusion scintigraphy before and 2 weeks after the surgical
procedure are shown in Table 2.
Pathologic Findings
The resected specimens were divided into 3 parts: the
main body of the tumor (Figure 1, A), the metastasized
PAS embolus in the distal segmental pulmonary artery
(Figure 1, B), and the superimposed thromboembolism dis-
tal to the PAS (Figure 1,C). Themain body of the tumor was
a gray-white firm gelatinous polypoidal mass, 6 to 10 cm in
length, and 3.5 to 5 cm in width. The tumor specimens of 7
patients took the shape of the main pulmonary artery and
extended to the segmental pulmonary artery, adhering to
the vascular wall and pulmonary valve. Macroscopic exam-
ination of the resected specimen showed a gelatinous, pol-
ypoid mass. The diagnosis and histologic classification
were made by the reference pathologists in Beijing Anzhen
Hospital. Pathologists performed the immunohistochemis-
try staining according to published protocols,4,5 with
antibodies against muscular actin, vimentin, h-caldesmon,
CD34, CD117, S-100, smooth muscle actin, desmin, and
CD68. Histologic and immunohistochemical diagnoses of
the 9 patients are shown in Table 1.
Late Results
As Table 3 shows, the 5 patients (patients 1–5) not receiv-
ing distal embolectomy died 6 to 29 months after tumorpulmonary artery sarcoma
cation Size (cm), length 3 diameter Origin of tumor
8 3 5 Right pulmonary artery
mas 7 3 4.5 Pulmonary trunk
rcoma 8 3 4.5 Pulmonary trunk
7 3 5 Pulmonary trunk
10 3 4.5 Pulmonary trunk
9 3 3.5 Right pulmonary artery
6 3 3 Pulmonary trunk
8.5 3 4.5 Pulmonary trunk
9 3 4.5 Pulmonary trunk
ma.
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TABLE 2. Comparison of residual occluded pulmonary segment as scannedwith pulmonary ventilation/perfusion scintigraphy before and 2 weeks
postprocedure
PAS resection with distal embolectomy (n ¼ 4) PAS resection without distal embolectomy (n ¼ 5)
P(t)Preoperative Postoperative Preoperative Postoperative
Ventilation/perfusion
scintigraphy
15  1.83 2.0  0.82 14.6  1.52 4.8  1.3 .7294* (0.3600)
P(t) .0001 (12.9655) 0.0001 (10.9562) .0074y (3.7227)
*P value for the t test before the procedure between the 2 groups. yP value for the t test 2 weeks postprocedure between the 2 groups.
Gan et al Acquired Cardiovascular Diseaseresection, with a median survival of 10 months (mean,
12. 6  8. 3 months). Among the 4 patients who received
distal embolectomy, 3 died 30, 37, and 43 months after
the procedure, and 1 is still alive 39 months after the proce-
dure. The patients who received distal embolectomy are
surviving longer than those without distal embolectomy
(log-rank test, x2¼ 7.914, P¼ .005). The causes of 8 deaths
were all related to the recurrence of PAS. The pattern of re-
currence was local recurrence in 4 patients (patients 1, 3, 4,
and 6) and distant metastasis in 6 patients (patients 2, 4, 5, 6,
7, and 8). The site of metastasis was lung in 5 patients (pa-
tients 3, 4, 5, 6, and 8), brain in 1 patient (patient 2), bone in
1 patient (patient 4), liver in 3 patients (patients 4, 6, and 7),
and right thorax wall in 1 patient (patient 1).A
C
DDISCUSSION
PAS is a rare tumor, and only a few hundred cases have
been reported in the literature.6,7 Because the clinical
symptoms of patients with PAS are often insidious and
nonspecific, it is difficult to make an early diagnosis of
this uncommon disease.8 Therefore, PAS is usually detected
at an advanced stage, which renders curative resection
nearly impossible.9 The prognosis of PAS is extremelyFIGURE 1. Resected specimen from patient 9. A, Main body of the PAS.
B, Metastasized PAS embolus in the distal segmental pulmonary arteries.
C, Superimposed thrombosis.
The Journal of Thoracic and Carpoor. The natural course of the disease is determined by
local tumor growth and additional superimposed thrombo-
sis and metastasized tumor emboli, both of which lead to
progressive obstruction of the pulmonary vessels.10 The
median survival of untreated patients is as short as 1.5
months (range, 1.5–5.5 months),11,12 with decompensate
heart failure as the primary cause of death.13 Surgery re-
mains the mainstay of treatment for PAS because early rad-
ical resection offers the only chance for a potential cure.
Treatment with aggressive resection lengthens the median
survival time to 10 months, with rare reports of patients re-
maining tumor-free 5 years after the initial surgery.14 Bacha
and colleagues15 retrospectively analyzed 23 patients with
PAS who underwent surgical therapy. The actuarial 3- and
5-year survivals of the resected patients were both 69%.
They concluded that a resection of the primary PAS could
produce an acceptable survival if the resection was
complete.
The surgical interventions include ‘‘shelling out’’ the
tumor concomitant with pulmonary artery thromboendar-
terectomy, pneumonectomy with or without CPB support,
and extended resection with major reconstruction.16 Many
tumors are not completely resectable at the time of the diag-
nosis, and palliative surgery plus thromboendarterectomy
may be the only option. Even with surgical therapy, the
prognosis is poor. Complete resection remains the main
factor affecting survival in patients after resection. Because
of the difficulty of distal pulmonary segment embolectomy
or unawareness of its importance, most cardiac surgeons
perform only a PAS resection without distal pulmonary
embolectomy, leaving the superimposed thrombosis and
metastasized PAS emboli in the distal segmental pulmonary
arteries unattended. As Table 2 shows, the pulmonary
ventilation/perfusion scintigraphy scanned 2 weeks after
the resection procedure revealed that distal embolectomy
may further evacuate the distal pulmonary emboli, thus
reducing the probability of residual occlusion of the pulmo-
nary segments.
Currently, the best results are obtained with the resection
of the tumor and its implantation site, followed by recon-
struction of the main pulmonary artery with a pericardium
homograft.17 Associated pneumonectomy has not shown
survival benefit in the small series analyzed retrospectively.
Concomitant chemotherapy and radiotherapy seem todiovascular Surgery c Volume 142, Number 6 1471
TABLE 3. Operative procedures and postoperative outcomes of patients with pulmonary artery sarcoma
Patient
No. Operative procedure Adjuvant treatment Recurrence Outcomes
1 PAS resection Radiation therapy Yes, right thorax Died at 6 mo
2 PAS resection Chemoradiation therapy Yes, brain Died at 11 mo
3 PAS resection No Yes, lung Died at 7 mo
4 PAS resection Chemoradiation therapy Yes, liver, lung,
adrenal gland, bone
Died at 10 mo
5 PAS resection Chemotherapy No Died at 29 mo
6 PAS resectionþdistal embolectomy Chemotherapy Yes lung, liver Died at 43 mo
7 PAS resectionþdistal embolectomyþCABG Radiation therapy No Died at 30 mo
8 PAS resectionþdistal embolectomy Chemoradiation therapy No Died at 37 mo
9 PAS resectionþdistal embolectomy No No Alive at 39 mo
PAS, Pulmonary artery sarcoma; CABG, coronary artery bypass graft. Distal embolectomy includes the evacuation of the superimposed thrombosis and metastasized PAS em-
bolus in the distal segmental pulmonary artery branches.
Acquired Cardiovascular Disease Gan et al
A
C
Dimprove midterm survival (1–2 years). As Figure 1 shows,
appositional thrombosis covering the tumor in the distal
or proximal part of PAS may complicate the diagnosis
and therapeutics of the PAS. The superimposed thrombosis
and metastasized PAS emboli in the distal segmental pul-
monary arteries could only be evacuated with embolectomy
distal to the PAS. Our data suggest that embolectomy distal
to the PAS may further extend patient survival. According
to Blackmon and Reardon,18 future approaches in treating
this deadly disease will include better biologic treatments
with possible ‘‘maintenance’’ chemotherapy, complete car-
diac excision and replacement with a mechanical device to
enable radical resection, and use of cardiotoxic chemother-
apy without penalty. Distal embolectomy is an effort to ap-
proach complete cardiac excision of PAS, so we think it is
worth further study for its survival benefits to patients
with PAS.Study Limitations
This study is a retrospective analysis of a small case se-
ries; therefore, some confounding factors may be involved
to show a significant association between prognosis and dis-
tal embolectomy. The small number of patients made statis-
tical validity meaningless, so the results from this study are
preliminary and not conclusive. More case reports or series
reports for this rare entity would allow us to reduce potential
bias. Despite this limitation, our findings provide sugges-
tions for inclusion of distal embolectomy in the surgical
procedure as a future direction for treatment of PAS.CONCLUSIONS
Radical surgical resection provides the only chance of
survival for patients with pulmonary artery sarcoma, and
distal embolectomy may further extend survival for these
patients.1472 The Journal of Thoracic and Cardiovascular SurReferences
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